Skip to main content
Nature Portfolio logoLink to Nature Portfolio
. 2023 Nov 27;24(1):79. doi: 10.1038/s41577-023-00976-5

Author Correction: Protein kinases: drug targets for immunological disorders

Leslie Castelo-Soccio 1, Hanna Kim 2, Massimo Gadina 3, Pamela L Schwartzberg 4, Arian Laurence 5,6,, John J O’Shea 7
PMCID: PMC10966199  PMID: 38012368

Correction to: Nature Reviews Immunology 10.1038/s41577-023-00877-7, published online 15 May 2023.

In the version of the article initially published, there was an error in Fig. 2 where pembrolizumab was included but has been removed as it is not a protein kinase inhibitor. In Table 3, a dividing line between Povorcitinib and Tofacitinib was missing and has now been added. These corrections have been made to the HTML and PDF versions of the article.


Articles from Nature Reviews. Immunology are provided here courtesy of Nature Publishing Group

RESOURCES